Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Cancer Cell
; 40(6): 590-591, 2022 06 13.
Article
in English
| MEDLINE | ID: covidwho-1850767
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
COVID-19 Drug Treatment
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Cancer Cell
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
J.ccell.2022.05.007
Similar
MEDLINE
...
LILACS
LIS